San Francisco-based Mammoth Biosciences has closed on a $150 million Series D led by Redmile Group, fast on the heels of its $45 million Series C raised in November 2020.
Subscribe to the Crunchbase Daily
With its most recent funding, the company is now valued at $1 billion and joins the Crunchbase Unicorn Board.
Trevor Martin, CEO and co-founder of Mammoth Biosciences
We spoke with Trevor Martin, CEO and co-founder of Mammoth Biosciences on its CRISPR applications. CRISPR is a technology that permits gene editing by finding a specific piece of DNA in a cell.
“We’ve been able to develop proteins to have …
Related posts:
The Week’s 10 Biggest Funding Rounds: Amazon Aggregator Thrasio, Productivity Software And Healthtec...
The Briefing: Udemy Slips In First Day On Nasdaq, Kurly Eyes Market Debut, And More
VC Dealmaking Has Reached a Crescendo, But This Isn’t 1999 All Over Again
The Briefing: CRED Picks Up $251M, Delivery Hero Backs Gorillas, And More
